Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling

PURPOSE: Currently, the exact role of estrogen receptor (ER) signaling in pancreatic cancer is unknown. Recently, we showed that expression of phosphorylated ERβ correlates with a poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). Here, we hypothesized that raloxifene, a FDA-ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Pozios, Ioannis, Seel, Nina N., Hering, Nina A., Hartmann, Lisa, Liu, Verena, Camaj, Peter, Müller, Mario H., Lee, Lucas D., Bruns, Christiane J., Kreis, Martin E., Seeliger, Hendrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906944/
https://www.ncbi.nlm.nih.gov/pubmed/32940862
http://dx.doi.org/10.1007/s13402-020-00559-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906944/
https://www.ncbi.nlm.nih.gov/pubmed/32940862
http://dx.doi.org/10.1007/s13402-020-00559-9

Ejemplares similares